Cognitive variability—A marker for incident MCI and AD: An analysis for the Alzheimer's Disease Neuroimaging Initiative
Abstract
The potential of intra‐individual cognitive variability (IICV) to predict incident mild cognitive impairment (MCI) or Alzheimer's disease (AD) was examined and compared to well‐established neuroimaging and genetic predictors.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2016
- Source ID
- 10.1016/j.dadm.2016.05.003
Entities
People
- Carey E. Gleason
- Derek Norton
- Emre Umucu
- Eric D. Anderson
- Jana Jones
- Mary Huber
- Michelle Wahoske
- Rebecca L. Koscik
- Sanjay Asthana
- Sterling C. Johnson
- The Alzheimer’s Disease Neuroimaging Initiative*
- Zhanhai Li
Organizations
- AbbVie
- BioClinica
- Biogen
- Canadian Institutes of Health Research
- Chiron Corporation
- Eli Lilly and Company
- Foundation for the National Institutes of Health
- GE HealthCare
- Geriatric Research Education and Clinical Center
- Laboratoires Servier
- Lundbeck
- Merck & Co.
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Norman Cousins Center for Psychoneuroimmunology
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- United States Department of Defense
- University of Wisconsin–Madison
- Wright State University